A Toronto court on September 23, 2026 overturned a provincial decision that denied a young father with Stage 4 melanoma coverage for treatment abroad, directing the Ontario Health Insurance Plan to conduct a third review. The ruling found that the Ontario government had not provided any justification for refusing the out‑of‑country care request.
The patient, diagnosed with advanced melanoma, had applied for special authorization to receive cancer therapy not available within the province. Ontario’s health insurance system generally excludes medical services performed outside Canada, but it does permit individuals to seek a discretionary review when a treatment is deemed necessary. The initial denial was challenged, leading to a second review that also rejected the request. The court’s latest order now requires the province to reassess the case for a third time.
In its decision, the court emphasized that the government’s refusal lacked an articulated basis, a procedural shortfall that warranted further examination. By mandating an additional review, the judge signaled that the province must supply clear reasoning when it declines to fund overseas medical interventions, especially for patients facing terminal illness.
The outcome underscores the procedural expectations placed on Ontario’s health officials when evaluating exceptional cases under the OHIP framework. While the plan’s standard policy excludes coverage for treatment abroad, the legal avenue for special authorization remains open, provided the government can substantiate its determinations. The young father’s case now proceeds to another assessment, offering the possibility of accessing the needed therapy pending the review’s conclusions.
The court’s order does not guarantee approval of the treatment but ensures that the provincial authorities must present a documented rationale for any future denial. This development may influence how similar requests are handled by OHIP moving forward.